ALAR PHARMACEUTICALS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 273.5 TWD | -1.97% |
|
-8.22% | +30.55% |
| 14/03 | Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 07/03 | Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan | CI |
| Sales 2022 | 800K 24.54K 2.05M | Sales 2023 | 469M 14.39M 1.2B | Capitalization | 11.94B 366M 30.55B |
|---|---|---|---|---|---|
| Net income 2022 | -19M -583K -48.61M | Net income 2023 | 383M 11.75M 980M | EV / Sales 2022 | 7,589 x |
| Net cash position 2022 | 484M 14.83M 1.24B | Net cash position 2023 | 895M 27.44M 2.29B | EV / Sales 2023 | 23.5 x |
| P/E ratio 2022 |
-330
x | P/E ratio 2023 |
31.2
x | Employees | 22 |
| Yield 2022 * |
-
| Yield 2023 |
0.72% | Free-Float | 57.52% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.97% | ||
| 1 week | -8.22% | ||
| Current month | -9.59% | ||
| 1 month | -9.59% | ||
| 3 months | +6.42% | ||
| 6 months | +31.81% | ||
| Current year | +30.55% |
1 week
263.00
306.50
1 month
263.00380.00
Current year
194.00465.00
1 year
116.00465.00
3 years
42.80465.00
5 years
42.80465.00
10 years
42.80465.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yung Shun Wen
CEO | Chief Executive Officer | - | 23/16/23 |
Vivian Kang
DFI | Director of Finance/CFO | - | 16/19/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Lin
CHM | Chairman | - | 23/16/23 |
Yung Shun Wen
CEO | Chief Executive Officer | - | 23/16/23 |
Cheng Yu Fang
BRD | Director/Board Member | - | 07/18/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 273.5 | -1.97% | 511,534 |
| 29/24/29 | 279 | +3.91% | 710,647 |
| 26/24/26 | 268.5 | -7.41% | 1,488,054 |
| 25/24/25 | 290 | -2.85% | 374,061 |
| 24/24/24 | 298.5 | -1.00% | 349,955 |
End-of-day quote Taipei Exchange, April 30, 2024
More quotes
Alar Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The Company mainly develops long-acting drugs for the treatment of opioid use disorder, treatment-resistant depression, and Parkinson disease. The main products include ALA-1000, buprenorphine subcutaneous long-acting sustained-release injection, is indicated for indicated for opioid use disorder (OUD); ALA-1300, subcutaneous injection, is indicated for opioid addiction; ALA-3000, ketamine subcutaneous long-acting sustained-release injection, is indicated for treatment-resistant depression (TRD); ALA-4000, apomorphine subcutaneous long-acting sustained-release injection, is indicated for Parkinson disease (PD); and ALA-2000, subcutaneous injection, is indicated for alcohol addiction and opioid use disorder. The Company distributes ALA-1000 and related products to the United States, France, Germany, the United Kingdom, Italy, and Japan markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +30.55% | 572M | |
| +3.37% | 69.85B | |
| +13.10% | 8.98B | |
| -12.75% | 4.89B | |
| +42.38% | 4.44B | |
| +5.23% | 3.95B | |
| +21.69% | 2.49B | |
| -19.05% | 2.4B | |
| -28.72% | 2.28B | |
| +11.13% | 1.96B |
- Stock Market
- Equities
- 6785 Stock
